sponsored
PatientsVille.com Logo

PatientsVille

Oxycontin Medical Research Studies

Up-to-date List of Oxycontin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Oxycontin Medical Research Studies

Rank Status Study
1 Recruiting Abuse Liability of Controlled-Release Oxycodone Formulations
Condition: Substance-Related Disorders
Interventions: Drug: Apo-Oxycodone CR®;   Drug: OxyNEO®;   Drug: Oxycontin®;   Drug: Placebo
Outcome Measures: Change from Baseline on Visual Analogue Scale for "Drug Liking" Over 8 Hours After Drug Administration;   Change from Baseline on Visual Analogue Scale for "Drug High" Over 8 Hours After Drug Administration;   Pupil Diameter;   Cmax;   Profile of Mood States (POMS);   Psychomotor Performance;   Visual Analogue Scale for "Any Drug Effects";   Visual Analogue Scale for "Good Effects";   Visual Analogue Scale for "Bad Effects";   Visual Analogue Scale for "Feel Sick";   Visual Analogue Scale for "Nausea";   Visual Analogue Scale for "Sleepy";   Visual Analogue Scale for "Dizzy";   Sedation;   Euphoria;   Dysphoric Changes;   Psychotomimetic Changes;   Somatic Disturbances;   Sensory Disturbances;   Tmax
2 Recruiting A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to Oxycontin in Korean Cancer Patients
Condition: Cancer
Intervention: Drug: oxycodone and naloxone
Outcome Measures: Assess reduction of pain intensity;   Efficacy parameters including long term safety and efficacy
3 Recruiting Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery
Condition: Arthroplasty, Replacement, Hip
Interventions: Drug: Standard Care morphine hydrochloride;   Drug: Oxycodone
Outcome Measures: Composite score of complications;   Number of opioid boluses in the post-intervention surveillance room;   Time to obtain a VAS score < 30/100 (from the first administration; minutes);   Length of stay in the post-intervention surveillance room (minutes);   Total dose of opioids during the first 24 hours (mg);   Total number of opioid requestions (patient controlled analgesia = PCA);   Total number of opioid requestions accepted / refused (PCA);   Ramsay score;   Presence / absence of an overdose of morphine/oxycodone (Ramsay score > 4);   Presence / absence of an overdose of morphine/oxycodone (Ramsay score> 4);   Presence/absence of complications;   Patient satisfaction, VAS scale;   Pain while at rest at while moving (Visual Analog Scale);   DN4 score;   Length of hospital stay (hours)
4 Recruiting Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain
Condition: Postcraniotomy Pain
Interventions: Drug: Oxycodone;   Drug: Codeine
Outcome Measures: To determine the difference in the mean pain VAS scores in the oxycodone and codeine groups at 24hr.;   To look at the incidence of adverse events in the oxycodone and codeine groups.
5 Recruiting Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur
Condition: Pain, Postoperative
Interventions: Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Mobilization measured daily using Cumulated Ambulation Score.;   Pain intensity measured daily on a verbal rating scale;   Adverse effects;   Opioid consumption.;   Length of stay in Hospital
6 Not yet recruiting Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
Condition: Pediatric Surgical Patient
Intervention: Drug: oral oxycodone
Outcome Measure: Oxycodone, oxymorphone, noroxymorphone and noroxycodone serum levels
7 Recruiting Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Condition: Pain
Intervention: Drug: Oxycodone HCl controlled-release tablets
Outcome Measures: The number of participants with adverse events as a measure of safety.;   To characterize the efficacy and provide additional pharmacokinetics (PK) data of oxycodone hydrochloride controlled-release tablets
8 Not yet recruiting A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: GL2907;   Drug: Oxycontine CR 10mg
Outcome Measures: Cmax,ss;   AUCτ;   Tmax;   t1/2;   Vz/f;   CL/F;   Cmin,ss;   Cave,ss;   degree og fluctuation;   swing;   R
9 Unknown  Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: etoricoxib;   Drug: oxycodone
Outcome Measures: Proportion of patients achieving a > 30% reduction in avg daily pain intensity at treatment week 4 (Visit 4).;   Proportion of patients achieving a > 50% reduction in avg daily pain intensity at treatment week 5 (visit 4).
10 Not yet recruiting Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Oxycodone
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Concentration at time 24 hours (C24);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2)
11 Recruiting Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
Condition: Pain
Intervention: Drug: Oxycodone
Outcome Measures: Cmax of Oxycodone Oral Solution.;   Safety of Oxycodone Oral Solution in Pediatric Patients
12 Recruiting Targin Cancer Pain
Conditions: Cancer;   Pain
Interventions: Drug: Oxycodone/Naloxone;   Drug: Oxycodone
Outcome Measures: BFI-Bowel Function Index;   BPI-Brief Pain Index
13 Recruiting Targin for Non-cancer Pain
Condition: Non Cancer Pain
Intervention: Drug: Oxycodone/naloxone prolonged release tablets
Outcome Measures: Bowel function index(BFI) 12 Weeks;   Modified BPI-SF-Average Pain over the last 24 hours
14 Unknown  A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
Condition: Post Tonsillectomy Pain
Interventions: Drug: 0,1 mg/kg of oxycodone;   Drug: Morphine 0,1 mg/kg;   Drug: Dexamethasone 0,5 mg/kg;   Drug: NaCl 0,9%
Outcome Measures: The difference of needed rescue pain medication post operatively;   differences in adverse effects
15 Recruiting An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
Condition: Spinal Disorders Related Pain
Intervention: Drug: Oxycodone/Naloxone
Outcome Measures: 24hr pain intensity score (Numeric rating score: 0 -10);   EuroQol-5 Dimension(EQ-5D);   Overall satisfaction of Physicians and subjects
16 Not yet recruiting A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Conditions: Postoperative Pain;   Postoperative Nausea and Vomiting
Interventions: Drug: Targinact;   Drug: Oxycodone;   Procedure: Laparoscopic segmental colectomy
Outcome Measures: Prevalence of postoperative gut dysfunction;   Pain control;   Oral analgesia use;   Pain scores
17 Recruiting Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury
Condition: Pain
Interventions: Drug: Fentanyl;   Drug: Oxycodone/acetaminophen;   Drug: oxycodone/acetaminophen
Outcome Measures: Pain Level;   Nausea level;   Occurrence of adverse events
18 Recruiting Abuse Potential Study of PF-00345439
Condition: Opioid Users
Interventions: Drug: Capsule;   Drug: PF-00345439;   Drug: oxycodone
Outcome Measures: Drug Liking: Peak Effect (Emax);   High: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours;   High: Area Under Effect Curve (AUE) From 0-2 Hours;   Take Drug Again Effect at 24 Hours;   Overall Drug Liking;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour;   Chewing Duration;   Taste: Subjective Experience from Chewing;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-2 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-3 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-12 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-3 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours;   High: Area Under Effect Curve (AUE) From 0-1 Hour;   High: Area Under Effect Curve (AUE) From 0-3 Hours;   High: Area Under Effect Curve (AUE) From 0-12 Hours;   Good Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-1 Hour;   Feeling Sick: Area Under Effect Curve (AUE) From 0-2 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-3 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-12 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-1 Hour;   Nausea: Area Under Effect Curve (AUE) From 0-2 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-3 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-12 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour;   Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-3 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-12 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-3 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Effects: Peak Effect (Emax);   Nausea: Peak Effect (Emax);   Feel Sick: Peak Effect (Emax);   Sleepy: Peak Effect (Emax);   Dizzy: Peak Effect (Emax);   Pupillometry: Peak Effect (Emax);   Good Drug Effects: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour;   Drug Liking: Area Under Effect Curve (AUE) From 0-3 Hours;   Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours;   Drug Liking: Time to Maximum (Peak) Effect (TEmax);   High: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Good Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Feel Sick: Time to Maximum (Peak) Effect (TEmax);   Nausea: Time to Maximum (Peak) Effect (TEmax);   Sleepy: Time to Maximum (Peak) Effect (TEmax);   Dizzy: Time to Maximum (Peak) Effect (TEmax);   Pupillometry: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Peak Effect (Emax);   Texture: Subjective Experience from Chewing;   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Area under the curve (AUC);   Systemic Clearance (CL);   volume of distribution (Vd);   Half-Life (t1/2)
19 Recruiting Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Condition: Opioid Abuse
Intervention: Drug: pioglitazone
Outcome Measures: Subjective ratings of drug, mood, and physiological effects;   Analgesic responses using the cold pressor test
20 Recruiting RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Conditions: Cancer;   Cancer Pain
Interventions: Drug: Morphine;   Drug: Fentanyl;   Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Proportion of Non-Responder (NR) patients;   Proportion of full-responder

These studies may lead to new treatments and are adding insight into Oxycontin etiology and treatment.

A major focus of Oxycontin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Oxycontin